Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Smoking Status and Serum NSE Level, as Prognostic Factors in Adenocarcinoma of Lung

원발성 폐선암 환자에서 예후인자로 흡연 및 NSE 수치의 의의

  • Kim, Hee Kyoo (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine) ;
  • Ok, Chul Ho (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine) ;
  • Jung, Mann Hong (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine) ;
  • Jang, Tae Won (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine)
  • 김희규 (고신대학교 복음병원 내과) ;
  • 옥철호 (고신대학교 복음병원 내과) ;
  • 정만홍 (고신대학교 복음병원 내과) ;
  • 장태원 (고신대학교 복음병원 내과)
  • Received : 2005.03.08
  • Accepted : 2005.05.13
  • Published : 2005.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background : The incidence of lung adenocarcinoma, which is more prevalent in women and nonsmokers, is increasing. The aim of this study was to determine the prognostic factors of an adenocarcinoma of the lung. Material and method : The clinical information of patients diagnosed with an adenocarcinoma of the lung at the Kosin University Gospel Hospital from January 1994 to July 2004 was reviewed retrospectively. The survival time of these patients was analyzed by the patient's age, gender, performance status, weight loss, smoking history, location of the primary tumor, clinical stage, serologic tumor markers, and treatment modality. Results : For all 422 patients with an adenocarcinoma of the lung, 247 (58.5%) were male, and their mean age was 59.8 years the. The majority of patients were smokers (58.3%), and the tumors were located in the periphery (59.7%). In the smokers, the tumor was located more in the central airway compared to the non-smokers (42.8% vs. 31.9%, p=0.12). The overall median survival time was 390 days (95% CI;304-436 days). Univariate survival analysis revealed that an older age (${\geq}65$ years old), male, weight loss, smoker, central type, advanced clinical stage, elevated serum carcinoembryonic antigen (CEA, >5 ng/ml) and neuron specific enolase (NSE, >15 ng/ml), and the supportive care only were significantly poor prognostic factors. The median survival time was shorter in the smokers than nonsmokers (289 days vs. 533 days, p<0.001). In addition, it was also shorter in the elevated NSE group than in the normal range group (207 days vs. 469 days, p<0.001). Multivariate analysis showed that age, clinical stage, serum NSE, smoking status, and treatment modality were independent predictors of survival (hazard ratios: 1.68, 1.94, 1.92, 2.39 and 1.57, respectively). Conclusions : Smoking is an important prognostic factor in an adenocarcinoma of the lung, but not gender. This suggests that the better prognosis of women is more related with the lower rate of smoking. In addition, the elevated serum NSE is also an important prognostic in an adenocarcinoma of the lung.

배 경 : 전체 폐암 중 원발성 폐선암은 최근에 발생 빈도가 늘고 있다. 이번 연구는 원발성으로 발생한 폐선암의 예후 인자 특히, 성별, 흡연력 및 종양 표시자에 대해 알아보고자 하였다. 방 법 : 1994년 1월부터 2004년 7월까지 고신대학교 병원에 내원하여 폐선암으로 처음으로 진단된 환자들을 대상으로 후향적 조사를 시행하였다. 진단 당시 환자들의 나이, 성별, 신체활동도, 체중 감소 정도, 흡연력, 병변의 위치, 병기, 혈액내 종양표시자, 치료 유무 등에 따른 생존 기간을 조사하였다. 결 과 : 총 422명의 대상 환자 중 남자가 247명(58.5%)이었고, 평균 연령은 59.8세(30~89세)이었다. 흡연 여부를 확인할 수 있었던 환자 336명 중 흡연가가 196명(58.3%)으로 비흡연가보다 많았다. 병변의 위치는 말초형이 중심형보다 많았으며(각각 59.7%, 40.3%), 이중 흡연가의 중앙 부위율이 42.8%로서 비흡연가의 31.9%보다 다소 높았다(p=0.12). 전체 환자들의 중앙 생존기간은 370일(95% CI=304-436일)이었다. 예후인자의 단변량 분석에서 65세 이상, 남자, 3개월간 5%이상 체중감소, 흡연력, 병기, 혈청 CEA (>5 ng/mL) 및 NSE(>15 ng/mL) 상승, 그리고 대증 치료군에서 예후가 불량하였다. 이 중 비흡연가 및 흡연가의 중앙 생존기간은 289일 및 533일이었고(p<0.001), NSE수치가 증가된 군(>15 ng/ml)과 정상수치를 보이는 군은 각각 207일 및 533일이었다(p<0.001). 다변량 분석에서는 나이, 병기, 혈청 NSE수치, 흡연력 및 치료 유무가 생존에 큰 영향을 주는 인자였다(각각의 상대 위험도: 1.68, 1.94, 1.92, 2.39, 1.57). 결 론 : 폐선암 환자에서 흡연은 중요한 예후인자로서, 여성이 남성보다 생존율이 높은 것은 흡연과 연관이 있는 것으로 확인되었다. 종양 표식자 중에서는 혈청 NSE 수치가 예후에 영향을 미치는 것으로 생각된다.

Keywords

References

  1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S-49S https://doi.org/10.1378/chest.123.1_suppl.21S
  2. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-51 https://doi.org/10.1378/chest.126.2.347
  3. Kim JS, Park JY, Chae SC, Shin MC, Bae MS, Son JW, et al. Changing trends of clinical aspects in lung cancer from 1988 to 1996. J Korean Cancer Assoc 1999;31:112-9
  4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. Chest 2002;122:1037-57 https://doi.org/10.1378/chest.122.3.1037
  5. Sobue T, Suzuki T, Fujimoto I, Doi O, Tateishi R, Sato T. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habits. Jpn J Cancer Res 1991;82:33-9 https://doi.org/10.1111/j.1349-7006.1991.tb01742.x
  6. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thoracic Cadiovasc Surg 2000;119:21-6 https://doi.org/10.1016/S0022-5223(00)70213-3
  7. Maeda T, Ueoka H, Tabata M, Kiura K, Shiayama T, Gemba K, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicated poor prognosis. Jpn J Clin Oncol 2000;30:534-41 https://doi.org/10.1093/jjco/hyd139
  8. Andoh M, Gemma A, Takenaka K, Hisakatsu S, Yamada K, Usuki J, et al. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer. Intern Med 1994;33:271-6 https://doi.org/10.2169/internalmedicine.33.271
  9. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7 https://doi.org/10.1378/chest.111.6.1710
  10. Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest 1997;112:1474-9 https://doi.org/10.1378/chest.112.6.1474
  11. Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993;54:44-8 https://doi.org/10.1002/ijc.2910540108
  12. Brownson RC, Loy TS, Ingram E, Myers JL, Alavanja MC, Sharp DJ, et al. Lung cancer in nonsmoking women. Cancer 1995;75:29-33 https://doi.org/10.1002/1097-0142(19950101)75:1<29::AID-CNCR2820750107>3.0.CO;2-Q
  13. Mazzone PJ, Mekhail T, Arroliga AC. Is lung cancer in nonsmoker a different disease? Chest 2004;126:326-9 https://doi.org/10.1378/chest.126.2.326
  14. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001;61:1309-13
  15. Powell CA, Spira A, Derti A, De Lisi C, LiuG, Borczuk A, et al. Gene expression in lung adenocarcinoma of smokers and nonsmokers. Am J Respir Cell Mol Biol 2003;29:157-62 https://doi.org/10.1165/rcmb.2002-0183RC
  16. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutation of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23 https://doi.org/10.1158/0008-5472.CAN-04-2818
  17. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival. Chest 2004;125:27-37 https://doi.org/10.1378/chest.125.1.27
  18. Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, Marchand L. Smoking history and survival among lung cancer patients. Cancer Causes Control 1990;1:155-63 https://doi.org/10.1007/BF00053167
  19. Jang TW, Jung MH. Diagnostic usefulness of simultaneous measurement of serum tumor markers in lung cancer patients. Tuberc Respir Dis 1995;42:322-31 https://doi.org/10.4046/trd.1995.42.3.322
  20. Ebert W, Muley T, Drings P. Dose the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 1996;16:2161-8
  21. Burghuber OC, Worofka B, Schernthaner G, Veter N, Neumann M, Dudczak R, et al. Serum neuronspecific enolase is useful marker for small cell lung cancer. Cancer 1990;65:1386-90 https://doi.org/10.1002/1097-0142(19900315)65:6<1386::AID-CNCR2820650623>3.0.CO;2-9
  22. Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, et al. Tumor markers CEA, NSE, SCC, TPA and Cypra 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999;19:3613-8
  23. Hirsch FR, Skov BG. Neuroendocrine characteristics in bronchogenic adenocarcinoma and its clinical relevance. Lung Cancer 1993;10:209 https://doi.org/10.1016/0169-5002(93)90181-V
  24. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patient. Lung Cancer 2001;31:221-31 https://doi.org/10.1016/S0169-5002(00)00186-0
  25. Shimayama T, Ohnoshi T, Ueoka H, Horiguchi T, Kodani T, Segawa Y, et al. Serum neuron enolase (NSE) levels in patients with non small cell lung cancer. Nippon Kyobu Shikkan Gakkai Zasshi 1992;30:1097-102
  26. Ferrigno D, Buccheri G, Giordan C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:311-20 https://doi.org/10.1016/S0169-5002(03)00232-0
  27. Yesner R, Carter D. Pathology of carcinoma of the lung: changing patterns. Clin Chest Med 1982;3:257-89
  28. Pujol JL, Simony J. Laurent JC, Richer G, Mary H, Bousquet J, et al. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers. Cancer Res 1989;49:2797-802